Capricor Therapeutics Nears Regulatory Milestone with Key FDA Submission

Capricor Therapeutics is entering a pivotal period in its quest to secure U.S. approval for a treatment targeting Duchenne muscular dystrophy. The biopharmaceutical firm is finalizing the submission of its comprehensive HOPE-3 Phase 3 study report to the Food and Drug Administration (FDA), marking a critical juncture in the regulatory review for its cell therapy candidate, Deramiocel.

The immediate focus is on delivering extensive clinical data packages to the regulatory body. These documents are designed to provide the evidence of efficacy and safety required for the ongoing Biologics License Application (BLA). This submission builds upon positive study results from late 2025 and aims to satisfy the agency’s specific requirements for clinical Read more...